THE EFFECT OF GEOGRAPHY ON THE EFFICACY OF SIFALIMUMAB, AN ANTI-INTERFERON-ALPHA MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS

被引：0
|
作者：
Khamashta, M. [1 ]
Illei, G. [2 ]
Drappa, J. [2 ]
Wang, L. [2 ]
Greth, W. [2 ]
机构：
[1] St Thomas Hosp, Rayne Inst, Graham Hughes Lupus Res Lab, London, England
[2] MedImmune LLC, Gaithersburg, MD USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.3354
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0183
引用
收藏
页码：951 / 952
页数：2
相关论文
共 50 条
  • [1] The Effect of Geography on the Efficacy of Sifalimumab, an Anti-Interferon-Alpha Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus
    Khamashta, M.
    Illei, G.
    Drappa, J.
    Wang, L.
    Greth, W.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S40 - S41
  • [2] ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Furie, R.
    Merrill, J. T.
    Werth, V. P.
    Khamashta, M.
    Kalunian, K.
    Brohawn, P.
    Illei, G.
    Drappa, J.
    Wang, L.
    Yoo, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 168 - 168
  • [3] ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Furie, R.
    Merrill, J.
    Werth, V.
    Khamashta, M.
    Kalunian, K.
    Brohawn, P.
    Illei, G.
    Drappa, J.
    Wang, L.
    Yoo, S.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S4 - S4
  • [4] SIFALIMUMAB Anti-Human Interferon alpha Monoclonal Antibody Treatment of Systemic Lupus Erythematosus
    Haddley, K.
    [J]. DRUGS OF THE FUTURE, 2013, 38 (12) : 829 - 834
  • [5] Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
    Furie, Richard
    Merrill, J. T.
    Werth, V. P.
    Khamashta, M.
    Kalunian, K.
    Brohawn, P.
    Illei, G.
    Drappa, J.
    Wang, L.
    Yoo, S.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [6] Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)
    Khamashta, Munther
    Merrill, Joan T.
    Werth, Victoria P.
    Furie, Richard
    Kalunian, Kenneth
    Illei, Gabor G.
    Drappa, Jorn
    Wang, Liangwei
    Greth, Warren
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 (12) : 3530 - 3531
  • [7] Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
    Narwal, Rajesh
    Roskos, Lorin K.
    Robbie, Gabriel J.
    [J]. CLINICAL PHARMACOKINETICS, 2013, 52 (11) : 1017 - 1027
  • [8] Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
    Rajesh Narwal
    Lorin K. Roskos
    Gabriel J. Robbie
    [J]. Clinical Pharmacokinetics, 2013, 52 : 1017 - 1027
  • [9] Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
    Khamashta, Munther
    Merrill, Joan T.
    Werth, Victoria P.
    Furie, Richard
    Kalunian, Kenneth
    Illei, Gabor G.
    Drappa, Jorn
    Wang, Liangwei
    Greth, Warren
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (11) : 1909 - 1916
  • [10] Population Pharmacokinetics of Sifalimumab, An Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus Patients
    Narwal, Rajesh
    Roskos, Lorin
    White, Wendy
    Greth, Warren
    Robbie, Gabriel
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S546 - S546
12345